Human epidermal growth factor receptor-2 (HER2) is a receptor tyrosine kinase directly linked to the growth of malignancies from various origins and a validated target for monoclonal antibodies and kinase inhibitors. Utilizing a new approach with designed ankyrin repeat proteins (DARPins) as alternative binders, we show that binding of two DARPins connected by a short linker, one targeting extracellular subdomain I and the other subdomain IV, causes much stronger cytotoxic effects on the HER2-addicted breast cancer cell line BT474, surpassing the therapeutic antibody trastuzumab. We determined crystal structures of these DARPins in complex with the respective subdomains. Detailed models of the full-length receptor, constrained by its rigid domain structures and its membrane anchoring, explain how the bispecific DARPins connect two membrane-bound HER2 molecules, distorting them such that they cannot form signaling-competent dimers with any EGFR family member, preventing any kinase dimerization, and thus leading to a complete loss of signaling.
INTRODUCTION
The human epidermal growth factor receptor 2 (HER2, hErbB2) is a receptor tyrosine kinase expressed on the cell surface of nearly every cell in the human body. HER2 contributes to multiple signal transduction pathways, but mainly stimulates the HER3/PI3K/ Akt pathway and the mitogen-activated protein (MAP) kinase cascades, leading to cell survival and proliferation (Yarden and Sliwkowski, 2001; Craven et al., 2003) . HER2 amplification promotes tumorigenesis (Faber et al., 2010) , and human tumors and various tumor cell lines rely on HER2 signaling for their survival. Such cancer cells are often referred to as ''HER2-addicted'' (Moasser, 2007) .
Trastuzumab (Herceptin, Genentech) , a humanized monoclonal antibody binding to the extracellular subdomain IV of HER2 (HER2_IV), is effectively used in the clinic to treat patients with HER2-overexpressing breast cancers (Cobleigh et al., 1999; Finn and Slamon, 2003) . Besides exerting cytotoxic effects in vivo through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), trastuzumab mainly acts as a cytostatic agent inducing a G1 phase cell-cycle arrest in HER2-amplified cancer cells (Sliwkowski et al., 1999) . Inhibition of HER2 homodimerization (Ghosh et al., 2011) and of HER2/HER3 heterodimerization (Junttila et al., 2009 ) is thought to be responsible for this antiproliferative effect. Pertuzumab (Perjeta, Genentech), a humanized monoclonal antibody binding next to the dimerization arm on subdomain II of HER2, shows only moderate antitumor effects in vitro on HER2-overexpressing breast cancer cell lines (shown for SkBr-3 cells; Schaefer et al., 1997) . However, for cell lines with normal HER2 expression levels that are grown in the presence of the HER3-activating ligand Heregulin, which efficiently stimulates HER2/HER3 heterodimer formation (Sliwkowski et al., 1994) , the effect of pertuzumab exceeds the effect of trastuzumab (Schaefer et al., 1997) . This finding can be explained in that pertuzumab, bound next to the HER2 dimerization arm, sterically blocks the formation of back-to-back heterodimers that are induced by ligand stimulation of HER3 (Franklin et al., 2004) .
Recently, Trastuzumab emtansine (T-DM1) (Kadcyla), a maytansinoid conjugate (Burris et al., 2011; Verma et al., 2012) , has become Food and Drug Administration approved. It is thought to be endocytosed with the slow internalization and recycling rates intrinsic to ErbB2 and thus to release the toxin. These encouraging data stimulate the search for novel mechanisms of action, which may pave the way for agents not requiring a conjugated toxin.
Recent studies on the regulation of the homologous receptor EGFR have shown that receptor dimerization is required, but may not be sufficient for full receptor activation Endres et al., 2013) . Dimerization of ECD, transmembrane (TM) helices and, as a consequence, the kinase domains have to take place in a well-ordered mechanism, requiring, for example, pairing the N-terminal, but not the C-terminal, parts of the two TM-helices for functional dimerization of the kinase domains. Additional factors modifying the coupling between dimerization of the extracellular domain to the dimerization and activation of the kinase domain may contribute to the subtle regulation of receptor activity Endres et al., 2013) .
Tumor cells becoming refractory to trastuzumab treatment present a major clinical problem. This is caused not only by downregulation or loss of HER2 expression, but also by various mutations bypassing the blocked HER2-signaling, including constitutive activation of the PI3K-signaling pathway, accumulation of a constitutively active HER2-kinase, and crosstalk of HER2 with other growth factor receptors (Xia et al., 2004; Sergina et al., 2007) . Acquisition of trastuzumab resistance might be promoted by the cytostatic effect of trastuzumab, which allows the tumor to undergo a directed evolution to escape treatment. Thus, an optimal drug against HER2-overexpressing cancer cells would have to be cytotoxic instead of cytostatic, but the cytotoxicity should not broadly aim at all HER2-expressing cells, but rather specifically target cancer cells that are dependent on HER2.
The concept that HER2 remains the active oncogenic driver in many cancer cells (e.g., by signaling through HER2-HER3-heterodimers) motivates further research for alternative molecular therapies targeting HER2 (Gajria and Chandarlapaty, 2011) . To expand and complement existing anti-HER2 therapies beyond pertuzumab and trastuzumab or any toxin conjugates, such as T-DM1 (Burris et al., 2011) , further HER2 binders that employ alternative mechanisms should thus be developed for abolishing HER2-dependent signaling.
Designed ankyrin repeat proteins (DARPins) are binding scaffolds that have recently been developed to expand the range of formats and applications beyond what is possible with immunoglobulin-based proteins (Binz et al., 2004; Boersma and Plü ckthun, 2011) . Because of their small size, high stability, and efficient folding, DARPins can easily be fused to each other in different orientation and geometries and to different protein domains to generate multivalent or multispecific constructs or to provide targeting specificity to effector proteins. They are highly suitable for site-specific chemical modification , such as coupling to polyethylene glycol (PEGylation) to increase the hydrodynamic radius and thus serum half-life and thereby promote tumor uptake (Zahnd et al., 2010) or conjugation of toxins. While they have been used for targeting toxins to a tumor (Martin-Killias et al., 2011) , it is of interest to investigate whether they can also exert a biological function by themselves. Thus, they appear predestined as binding moieties for novel approaches in targeted therapy. DARPins recognizing the soluble recombinant ectodomain of HER2 (HER2-ECD) with subnanomolar to low-nanomolar affinities were selected by ribosome display (Zahnd et al., 2007) and phage display (Steiner et al., 2008) . These HER2-specific DARPins have been used for histochemical staining (Theurillat et al., 2010) , for tumor targeting of toxins (Zahnd et al., 2010) , and for targeting adenoviral (Dreier et al., 2013) and lentiviral vectors (Mü nch et al., 2011) to HER2-overexpressing cells.
In this paper, we demonstrate the cytotoxic activity of bispecific DARPin constructs against the HER2-addicted cell line BT474, a widely used model system for testing anti-HER2 activity in vitro. The bispecific DARPins not only induce a cytostatic effect like trastuzumab, but also act as specific cytotoxic agents. This cytotoxic effect does not rely on any conjugated toxin, but is intrinsic to the binding mechanism.
The results were confirmed on a broad panel of breast tumor cell lines and tumor models developed by R.T. and colleagues (R.T., M.S., C.J., D.C. Schaefer, G. Nagy-Davidescu, M. Gö ranson, A.H., and A.P., unpublished data), who proceeded to characterize in great detail the influence of these constructs on various aspects of downstream signaling, such as phosphorylation pattern, downstream kinase activity and apoptotic markers. They showed that the most potent of the bispecific DARPins cause a persistent inhibition of both the phosphatidyl-inositol-3-kinase (PI3K-AKT/PKB) and the RAS-RAF-MAPK pathway, leading to a strong apoptotic response.
Based on the X-ray structures of three DARPins in complex with the cognate HER2-ECD subdomain we have determined here, we propose a model of how such a complete shutdown of HER2-dependent signaling is achieved.
RESULTS

Epitope Mapping of HER2-Binding DARPins
DARPins that had been selected by phage display (Steiner et al., 2008) or ribosome display (Zahnd et al., 2007) to target the fulllength ectodomain of HER2 without showing any cross-specificity against other EGFR-family members were characterized to determine which of the four HER2 subdomains forms the epitope. Since DARPins typically recognize conformational epitopes, we expressed subdomains alone and in combination in insect cells using a baculovirus system (Supplemental Experimental Procedures available online). To minimize glycosylation for subsequent crystallization, we replaced the Asn residues in predicted N-linked glycosylation sites by Asp. ELISAs on these proteins showed that the epitopes recognized by DARPins 9_26 and 9_29 are located on HER2-I, while DARPin G3 bound to HER2-IV ( Figure S1A ). Competition for binding to HER2-overexpressing cells measured by flow cytometry revealed that DARPins 9_26 and 9_29 compete for the same epitope (Figure S1B) . DARPin G3, which binds to HER2 subdomain IV, did not compete with trastuzumab but competed with a different HER2-specific DARPin, H_14, which in turn competed with trastuzumab.
Construction of Bispecific Binders Targeting Different Epitopes
Various bivalent and bispecific constructs were generated by genetically fusing two DARPins by (G 4 S) n linkers of different lengths. To target two nonoverlapping epitopes with a single molecule, DARPins 9_29 or 9_26 were connected to DARPin G3 by a 20-amino-acid linker, with either an ECD-I binder at the N-terminal end and the ECD-IV binder at the C terminus or in opposite orientation. The four different bispecific binders [e.g., 9_26-(G 4 S) 4 -G3, abbreviated ''6_20_G'' for the two DARPins and the linker length of 20 amino acids] were tested regarding their binding to HER2-overexpressing cells. G3 with a dissociation constant (K D ) of 90 pM (Zahnd et al., 2007) has the highest affinity of the three HER2 binders used in this study, compared to a K D of 1 nM for 9_26 and 1 nM for 9_29 (Steiner et al., 2008) . Kinetic experiments on cells in the presence of a competing DARPin (to prevent rebinding) revealed that the off-rates of the bispecific binders were ten times lower than the off-rates of monovalent G3 ( Figure 1A ; Table S1 ). The slower off-rate and lower K D of the bispecific constructs, compared to their monovalent building blocks, can be attributed to an avidity effect and indicates bispecific binding to HER2 on the cell.
Effects of Mono-and Bivalent Constructs on Cell Proliferation and Cell Death
We tested the influence of the different DARPin constructs on cell proliferation and cell survival in XTT assays, using BT474 cells as an example of a HER2-addicted cell line. MCF7-cells, which express HER2 at much lower levels than BT474 cells, were used as a control. Calibration experiments showed that a signal decrease by 60%, compared to untreated cells, corresponded to lack of cell proliferation over the 4 days of cell growth before the XTT assay; a larger decrease indicated cell death.
None of the monovalent DARPins characterized in this study affected the number of viable cells measured by the XTT assay ( Figure 1B) . Mixtures of two different DARPins proved to be Table S1 for fitted off-rates, Figure S1A for ELISA epitope mapping, and Figure S1B equally inert, as did control constructs in which one of the two DARPins in the bispecific molecule had been replaced by a non-HER2-binding DARPin (DARPin off7, targeting maltose-binding protein; Binz et al., 2004) (Figure 1C) . A monospecific bivalent DARPin, G_20_G, even stimulated cell proliferation ( Figure 1C ).
Bispecific constructs composed of a subdomain I binder at the N terminus and the subdomain IV binder at the C terminus (6_20_G or 9_20_G) showed a concentration-dependent decrease of cell viability by up to 75%, while treatment with trastuzumab decreased viability by 50% ( Figure 1D ). The constructs with reverse orientation (G_20_9) either lacked any effect on cell growth (G_20_6) or even slightly promoted cell growth. Similar to trastuzumab, bispecific constructs did not affect the cell proliferation of MCF7 cells ( Figure 1E ), suggesting the restriction of the observed effects to HER2-addicted cells. Comparison of constructs with 5, 10, 20, 30 and 40 amino acid linkers showed that for 9_x_G constructs, specific activity and potency decreases with increasing linker length. The most potent constructs proved to be 6_5_G and 9_5_G, with (G 4 S)-linkers of only five amino acids. They decreased the cell viability in XTT-assays after 4 days of growth by more than 80%, as compared to untreated cells, and showed a half-maximal effect already at a concentration of less than 100 pM compared to ca. 1 nM for 6_20_G and 9_20_G. Conversely, increasing the linker length to forty amino acids, as in 6_40_G and 9_40_G, decreased the biological activity (growth reduction of only 40%) ( Figure 1F ). The constructs with inverse orientation, G_x_6 and G_x_9, inactive or even stimulatory at a linker length of 20 amino acids, gained anti-proliferative activity at short linker lengths, but the best construct was found to be only as active as trastuzumab ( Figure 1G ).
Neither the single DARPins nor the bispecific constructs affected internalization or degradation of HER2, as determined by flow cytometry (R.T., M.S., C.J., D.C. Schaefer, G. NagyDavidescu, M. Gö ranson, A.H., and A.P., unpublished data).
X-Ray Crystal Structures of Complexes HER2_I:9_29, HER2_I:9_26, and HER2_IV:G3
The structures of the complexes of HER2_I with DARPin 9_29 and with 9_26 were determined at 2.55 Å and 3.2 Å resolution, respectively, the structure of HER2_IV in complex with G3 at 2.65 Å resolution. A summary of data collection statistics and refinement results is listed in Table 1 . Unliganded 9_26 was solved to 2.9 Å (unpublished data), unliganded G3 (Protein Data Bank [PDB] ID 2JAB) (Zahnd et al., 2007 ) to 1.7 Å . G3 and unliganded 9_26 contain the original DARPin C-cap, which by NMR had been shown, to some percentage, to show some transient unfolding in solution (Wetzel et al., 2010) . For crystallization in complex with HER2_I, this C-cap was replaced by an optimized C-cap (Mut5) (Interlandi et al., 2008) in DARPins 9_29 and 9_26, which does not give any sign of transient unfolding.
The asymmetric unit of HER2_I:9_29 contains one heterodimeric complex with seven intermolecular hydrogen bonds (Table  S2 ) and a buried surface area of 784 Å 2 (Figures 2A-2C ). In the 
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Structural Basis of Cytotoxic HER2-Binding DARPins asymmetric unit of HER2_I:9_26, two heterodimers are present. Due to the limiting quality of the HER2_I:9_26 data set, the slight differences that are visible between the two complexes of the asymmetric unit leave some minor uncertainty about the exact geometry of the binding of DARPin 9_26. Most of our analyses are therefore concentrated on the HER2_I:9_29 complex. However, despite the lower resolution of the HER2_I:9_26 structure compared to the HER2_I:9_29 structure, two crucial conclusions can be drawn from the presented structure: the buried surface area, and more importantly the orientation, of 9_26 are very similar to the mode of binding of the better resolved 9_29 to HER2_I. The asymmetric unit of the HER2_IV:G3 structure contains two heterodimeric complexes with 7 and 5 intermolecular hydrogen bonds between DARPin G3 and HER2_IV (Table S3) , respectively, and a buried surface area of 818 Å 2 (complexes
The conformation of HER2_I and HER2_IV is essentially the same as that of the respective subdomain in structures of the whole extracellular domain of HER2 Garrett et al., 2003; Franklin et al., 2004; Bostrom et al., 2009; Fisher et al., 2010) , with root-mean-square deviation (rmsd) values for the Ca-backbone around 0.49 to 0.81 Å for HER2_I and 0.24 to 0.68 for HER2_IV (Table S4 ; Figures S2A and S2B) , underlining the rigidity of the HER2 domains.
A comparison of the epitopes recognized by various HER2 binders in the Protein Data Bank (Figure 3) shows that the regions recognized by the three DARPins do not overlap with epitopes recognized by any of the other binders: scFv A21 binding to domain I (Zhou et al., 2011) , therapeutic antibody pertuzumab recognizing subdomain II (Franklin et al., 2004) , Z-domainderived affibody zHER2 recognizing the same epitope on domain III as Fab37 (Fisher et al., 2010) , and trastuzumab and its HER2/VEGF dual specific variant bH1 (Bostrom et al., 2009) binding to subdomain IV.
DARPins 9_29 and 9_26 bind to the same epitope on HER2_I, involving residues from the N-cap and the first two internal repeats ( Figure 4) . The third repeat and the C-cap make no contacts. The DARPin contacts two adjacent strands of HER2_I at the edge of this domain, including further interactions down the side perpendicular to the b helix axis of domain I, which is a member of the L-domain family. The high-affinity binding of DARPin 9_29 to HER2_I is governed by six hydrogen bonds, p-stacking, and extended hydrophobic interactions described in detail in Supplemental Experimental Procedures and Table  S2 . Epitope and paratope residues are highlighted in the sequence alignments shown in Figure S3 . Comparison of the sequence differences between the two DARPins to this contact map shows that 14 out of 19 contact residues are conserved. Figure S2 for superpositions of the HER2 subdomains on the full-length HER2_ECD and Table S4 for rmsd values.
Construct HER2-IV spans residues 509-604 of the HER2-ECD, omitting the last two disulfide bonds. Residues 581-604 are disordered in the structure. DARPin G3 binds to an epitope on the N-terminal half of subdomain IV (residues 513-564). The structure of G3 in the complex is well maintained compared to its uncomplexed structure (rmsd 0.65 or 0.55 Å ; Figure S2C ), demonstrating that the DARPin:HER2 complexes can, in a first approximation, be considered as rigid-body interactions. The paratope comprises both internal repeats and the C-cap of the DARPin (Figure 2 ; Figure S3 ). The long axis of the DARPin is at nearly a right angle to the long axis of HER2_IV, the DARPin b-turns facing toward the membrane. The DARPin wraps around the rod shaped Cys-rich domain IV, its slight curvature is fitting the target shape very well, explaining the high affinity of 90 pM. It contacts two protrusions, formed by the loop spanned by Cys 523 and 539 and the adjacent pair of interlocked disulfide bond. Two of the four mutations introduced during affinity maturation are directly involved in binding interaction. Of the 14 randomized residues, 9 are involved in specific contacts, as are several framework residues. Six hydrogen bonds and extended hydrophobic interactions, altogether contributed by 13 residues (Supplemental Experimental Procedures), are responsible for the picomolar affinity of G3. The atomic interactions are summarized in Table S3 . Thus, although G3 possesses only two internal repeats, the perfectly matching hydrophobic and hydrogen bonding interactions, contributed by adapted curvature as a result of directed evolution (Zahnd et al., 2007) , account for its high affinity.
Molecular Modeling of Full HER2 and DARPin-Inhibited States
Since the HER2 domains are very rigid and their structure did not change between the DARPin complexes and the whole ECD, we could easily place the DARPins on the full HER2_ECD (residues 1-620). We also built models of putative HER2_ECD homo-and heterodimers (see Supplemental Experimental Procedures for a detailed description of the modeling procedure), taking into account all available ErbB-family structures to make the models as realistic as possible. The DARPins bound to HER2_I and HER2_IV could be added to the HER2 monomer and dimer models without any clashes (Figures 5A-5D) .
To build a model of the whole receptor, the HER2-ECD model was combined with the NMR structures of transmembrane helices (PDB ID 2JWA; Bocharov et al., 2008) and the X-ray structures of the kinase domains (PDB ID 3PP0 for the active kinase dimer [Aertgeerts et al., 2011] and 3RCD for the inactive kinase [Ishikawa et al., 2011] ), taking the electron-microscopy-based models of Mi et al. (2011) as a guide. Seven residues between the last disulfide bridge of ECD domain IV and the start of the transmembrane helix and 30 residues between TM domain and kinase were treated as flexible to connect the domains.
The resulting models assume that initially both monomer and dimer stand upright on the membrane and that the HER2-ECD is as rigid as suggested previously Dawson et al., 2007) .
The distance between the C-term of the domain I-binding DARPin and the N-term of the domain-IV-binding DARPin is 130 Å on the same HER2 molecule ( Figure 5A ). For intramolecular binding to a HER2_ECD monomer in this orientation, 9_x_G, the linker would have to be even longer, as it needs to wrap around the monomer. However, the most active of our constructs has a linker length of a mere five amino acids, spanning no more than 17 Å , which thus excludes intramolecular binding ( Figure S4 ).
To connect two DARPins on the same side of the HER2 homodimer ( Figures 5C and 5D ), the linker would have to span at least 80 Å for the 9_x_G construct, and to connect DARPins on two independent monomers, the linker would have to span at least the difference in height above the membrane of the two termini, more than 50 Å . It follows that with the most active of our constructs, with a 17 Å linker, linking two HER2 molecules in either of these upright conformation is not possible.
Since the observed biological activity and increased binding avidity of the short-linkered constructs prove that the bispecific constructs do bind bivalently on cells, it follows that the HER2 molecules must arrange to accommodate this. For bivalent binding of 9_5_G to occur, the 9_29 epitope of HER2_I has to move closer to the membrane, and this requires either a major conformational change within the HER2_ECD (which is unlikely, as explained below), or a major change in the orientation of the whole HER2-ECD relative to the membrane, moving essentially as a rigid body.
Comparison of extracellular domain conformations in various different ErbB family crystal structures indicates that there are very few possibilities for major conformational changes within the HER2_ECD. The connection between subdomains I and II and between III and IV is quite rigid: the side chain of conserved Trp 183 of subdomain II inserting into the core of subdomain I and the side chain of Trp 499 of subdomain IV inserting into the core of domain III severely limit the flexibility of these interfaces. Major conformational changes within ErbB receptor extracellular domains appear to be limited to a rigid-body movement of the domain I-II pair relative to the domain III-IV pair around a pivot between domains II and III . HER1, HER3, and HER4 occur in two conformational states. In the presence of an activating ligand, their extracellular domain assumes an ''open'' conformation, similar to the default conformation of the HER2_ECD (Ogiso et al., 2002; Liu et al., 2012) , while their default conformation in the absence of a ligand and/or dimerization partner is a ''tethered'' conformation (Cho and Leahy, 2002; Ferguson et al., 2003; Bouyain et al., 2005) , which has so far not been observed for HER2. The HER2_ECD constitutively assumes an ''open'' conformation (Garrett et al., 2003) .
However, a rigid HER2_ECD could easily tilt relative to the membrane ( Figures 6D and 6G ). This would require flexibility in the short peptide segment between the last disulfide-bridged cysteine of the extracellular domain and the start of the transmembrane helix. Indeed, these residues are disordered in reported structures of the HER2 extracellular domain and in NMR structures of the transmembrane helix. Based on singlemolecule Fö rster resonance energy transfer analysis and fluorescence lifetime imaging microscopy, this region in EGFR has been proposed to be sufficiently flexible to allow the EGFR_ECD to equilibrate between an upright position and one lying flat on the membrane (Webb et al., 2008) . Thus, tilting the ECD in such a way that the dimerization loop points toward the membrane ( Figures 6D and 6G) would lower the C terminus of 9_29 (or 9_26, respectively) and raise the N terminus of G3 in such a way that the two can be connected by a short linker.
Alternatively, a hypothetical pseudo-tethered conformation of HER2, for which, however, there is currently no direct evidence, would bring the 9_29 epitope into an ideal position relative to the G3 epitope of a second HER2 monomer for intermolecular crosslinking with short-linkered constructs ( Figures 6C and 6F) , while intramolecular crosslinking within a tethered monomer would still require a 70 Å (G_x_9) to 80 Å (9_x_G) linker. Such a conformation would not interfere with DARPin binding, but would prevent the formation of back-to-back HER2 homo-and heterodimers.
The most important deduction from these models is that, by linking domain I of one HER2 molecule to domain IV of another by a short linker, the transmembrane domains of the two HER2 are forced apart. This conclusion is independent of the pivot point utilized and independent of the exact geometry of the HER2:DARPin:HER2 complex. The consequence of the DARPin-induced movement of domains I and IV of two different HER2 molecules is that it prevents the assembly of active kinase dimers.
DISCUSSION
The results presented in this paper and the associated models of the induced inhibited states of HER2 allow us to propose a mechanism of the induction of cytotoxicity within the framework of activation and inhibition of the ErbB receptor family. We present the X-ray structures of three DARPin:target complexes, with DARPins 9_29 and 9_26 binding to the same epitope on subdomain I of HER2, and DARPin G3 recognizing subdomain IV. The structures of the DARPins in complex with the cognate receptor domain can be superimposed on the structure of the full-length HER2 extracellular domain without any evidence for conformational changes in the individual domains beyond some very small local flexibility, already apparent from the comparison of the various structures of HER2_ECD in the Protein Data Bank. Thus, the superposition of the DARPins on the whole HER2 ECD is unambiguous.
Monomeric DARPins Do Not
Interfere with HER2 Signaling All tested monovalent DARPins that were used for the construction of the bispecific binders, individually or as a mixture, have no effect on the cell survival and proliferation of cultured BT474 cells, indicating that the monovalent DARPins do not interfere with HER2 signaling in this HER2-addicted cell line. Models of the putative HER2 ''back-to-back'' homodimer (Figure 6B) or of canonical heterodimers with EGFR or HER3 (not shown), which are generally thought to represent the active state of HER2, indicate indeed that the binding of unlinked (i.e., monovalent) DARPins should not interfere with homo-or heterodimerization, consistent with the observation that the monovalent DARPins are not biologically active. Since the monovalent DARPins cover both sides of the dimer, they should interfere with the lateral association of receptor dimers to produce tetramers or higher oligomers formed by stacking the planes defined by domains I, II, and III, as recently proposed (Zhang et al., 2012) . However, since the unlinked DARPins do not interfere with HER2 activity, higher oligomers associating in this specific manner cannot be required for the activity of HER2 measured in our assays.
Activity Depends on Linker Length
When connected by short flexible linkers, the two DARPins 9_29 and G3 acquire biological activity. While monospecific bivalent constructs, in particular G_20_G, activate HER2 signaling and have a proproliferative effect on BT474 cells, presumably by stabilizing HER2-HER2 homodimers, the bispecific bivalent constructs described here inhibit HER2 signaling and decrease cell viability, without affecting the number of receptors displayed on the cell surface (R.T., M.S., C.J., D.C. Schaefer, G. Nagy-Davidescu, M. Gö ranson, A.H., and A.P., unpublished data). Their activity is dependent on linker length and on domain orientation. Constructs with shorter linkers show higher activity than constructs with longer linkers, and constructs with N-terminal DARPin 9_29 and C-terminal DARPin G3 (9_x_G) show significantly higher activity than G_x_9, the opposite orientation, of the same linker length. While for the G_x_9 orientation the inhibitory activity already disappears with a linker length of 20 amino acids, in the 9_x_G orientation, even the construct equipped with a 40-amino-acid linker shows some activity.
Constructs in which one of the DARPins has been replaced by the nonbinding DARPin off7 are biologically inactive, demonstrating the need for bivalency. Therefore, we have to conclude that the biological activity of the bispecific constructs is indeed due to crosslinking of HER2 molecules and not to simple direct steric hindrance of HER2 homo-or heterodimerization by the DARPins.
The Linker Length Is Too Short for Both DARPins to Bind to the Same HER2 Monomer or Dimer
The linkers of the shortest and most potent of the bispecific constructs tested, 9_5_G, 9_10_G, and 9_20_G, are too short to connect the C terminus of 9_29 to the N terminus of G3 bound to the same HER2 molecule, in either the open conformation seen in all crystal structures of the HER2 ectodomain Franklin et al., 2004; Bostrom et al., 2009; Eigenbrot et al., 2010; Fisher et al., 2010) or in a hypothetical pseudo-tethered conformation modeled in analogy to the tethered conformations of other members of the ErbB family (Cho and Leahy, 2002; Ferguson et al., 2003; Bouyain et al., 2005; Li et al., 2005; Hollmé n et al., 2012; Liu et al., 2012; Ramamurthy et al., 2012) . The linkers are also too short to connect DARPins bound to the two HER2 monomers in a putative back-to-back HER2 homodimer. The observed bivalent binding, therefore, can only be explained by crosslinking of two independent HER2 monomers, at least one of which has to bend down (see below).
Orientation of HER2 on the Cell Surface
On the surface of intact cells, the transmembrane domain of the receptor is constrained to the plane of the membrane, restricting translational and rotational freedom of the receptors. Conventionally, receptors of the ErbB family are depicted as standing upright on the cell surface, with their main axis about perpendicular to the plane of the membrane. However, it has been proposed that a small percentage of EGFR, providing high-affinity EGF sites, can lie flat on the surface (Webb et al., 2008) , underlining the flexibility of the few residues between the receptor ectodomain and the TM helices to allow this. Therefore, a tilting of the whole ectodomain of HER2 with a pivot close to the membrane has some precedent.
Nonetheless, a completely flat orientation of HER2 dimers is inconsistent with binding of DARPins, as in the bound state Linker lengths in the various bispecific DARPins vary from 16.5 Å (9_5_G) to 132 Å (9_40_G), assuming a fully extended conformation ( Figure S4 ).
they would prevent a flat orientation, since DARPin epitopes would be located between receptor and membrane. Also, since the majority of receptors is standing upright in EGFR (Webb et al., 2008) , there must be a dynamic equilibrium, and any bound DARPin will shift this equilibrium away from any flat orientation. Considering the data on EGFR, it follows for HER2 that a tilted orientation of HER2 molecules in the DARPin-linked state is possible, but not a completely flat one. This flat orientation, which we can exclude, would be the only one in which the TM helices would be able to come close enough for the kinases to form an active dimer. Both models (B/F and C/G) enforce a large distance between the kinase domains, and both prevent further dimerization by the strong tilt of dimerization interfaces and/or by making the dimerization loop inaccessible. Both models would also be compatible with daisy-chaining, forming higher-order oligomers.
Conformational Flexibility of the HER2 Extracellular
between the last cysteine of domain IV and the transmembrane helix ( Figures 6D and 6G ).
Interference with HER2 Dimerization and Activation Either of the two discussed putative conformational changes captured by the bispecific DARPins leads to a situation where the back-to-back dimerization interface of HER2 is obstructed.
In any pseudo-tethered conformation, this obstruction is intramolecular; in any of the conceivable tilted conformations, it is due to the enforced proximity of the dimerization interface to the membrane. Either model, and all reasonably conceivable geometric variations of the models, would result in bringing the C terminus of DARPin 9_29 closer to the N terminus of DARPin G3. As the transmembrane helices cannot be pulled out of the plane of the membrane, this forces the membrane insertion points and therefore the transmembrane and intracellular kinase domains apart, independent of the pivot point.
For maximal inhibition, formation of larger oligomers formed by daisy-chaining may be required, where every receptor monomer is bound to two bispecific DARPins and both DARPin epitopes on HER2 are occupied. For linker lengths exceeding 20 amino acids, alternative, intramolecular binding modes may start to compete with the intermolecular binding modes enforced by the short linker, explaining their overall lower biological activity.
Conclusions
The contrast between the biological inertness of the monovalent DARPins alone or in combination, the stimulation of HER2 signaling by monospecific bivalent DARPin construct G_20_G and, on the other hand, the potent inhibition of HER2 signaling by bispecific DARPin constructs connected by a minimal linker is intriguing. Trivial explanations for the inhibitory activity of the bispecific constructs, such as receptor downregulation or direct steric hindrance of receptor dimerization, could be excluded (R.T., M.S., C.J., D.C. Schaefer, G. Nagy-Davidescu, M. Gö ranson, A.H., and A.P., unpublished data), leaving a model where the steric constraints imposed by the membrane anchoring of the receptors play an important role in forcing apart the transmembrane helices of two HER2 monomers connected by the bispecific DARPin constructs.
The large fraction of the HER2 dimer surface covered by the biologically inert monovalent DARPins challenges models that postulate a need for lateral tightly packed HER2-oligomers for certain aspects of HER2 signaling in the cell line described here. The strong inhibitory effect of the bispecific DARPin constructs makes them an interesting starting point for future tumor targeting constructs directed against HER2-addicted cancer cells. A detailed analysis of their effects on different aspects of downstream signaling is presented in a separate publication (R.T., M.S., C.J., D.C. Schaefer, G. Nagy-Davidescu, M. Gö ranson, A.H., and A.P., unpublished data).
In summary, the engineering of binding molecules that bispecifically target HER2 at domains I and IV, connected by a linker not commensurate with intramolecular binding or binding to back-to-back complexes, has proven to be a very promising way to expand the arsenal of molecular targeting of cancer cells that are addicted to this receptor. In this context, DARPins might be particularly promising, as they can be easily engineered in a variety of molecular orientations and equipped for prolonged systemic circulation in order to extend their outstanding in vitro potency for in vivo studies (R.T., M.S., C.J., D.C. Schaefer, G. Nagy-Davidescu, M. Gö ranson, A.H., and A.P., unpublished data).
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of DARPins All DARPins were purified essentially as described previously (Zahnd et al., 2010) . Proteins were overexpressed in E. coli XL1-Blue and purified via their N-terminal MRGSH 6 tag with nickel-nitrilotriacetic acid superflow resin (QIAGEN). For cloning of bispecific constructs, the DARPin ORFs were digested with BamHI and HindIII (New England Biolabs) and ligated into compatible expression vectors pQiBi, coding for different flexible (G 4 S) n linkers. This results in the connecting .AEILQKL(G 4 S) n RSDLGKKLL., where the first underlined sequence is from the C-cap of the N-terminal DARPin, the second underlined sequence is from the N-cap of the C-terminal DARPin and n indicates the number of pentapeptides present in the flexible linker.
Cell Culture BT-474 cells were obtained from the American Type Culture Collection (ATCC HTB-20). Cells were grown in complete RPMI 1640 medium (SigmaAldrich) supplemented with 10% (v/v) heat-inactivated FCS (PAA GmbH) and 100 U/ml penicillin/streptomycin (Sigma) in a humidified incubator with 5% CO 2 .
Flow Cytometry
Per assay, 1 3 10 6 cells were incubated with the respective fluorescently labeled DARPins at the indicated concentrations in 100 ml PBS_BA (PBS, 0.2% NaN 3 , 1% BSA). After incubation, cells were harvested by centrifugation (800 3 g, 30 s, 4 C) and washed twice using 1 ml PBS_BA, each. Flow cytometry was performed on a Cyflow space system (Partec). Recorded events were gated for FSC/SSC of single viable cells. Fluorescence data were analyzed using the FlowJo software. Dissociation experiments were performed as described in (Tamaskovic et al., 2012) . In brief, aliquots of 1 3 10 6 cells were preincubated with DARPin-AlexaFluor488-conjugates at 100 nM in PBS_BA for 1 hr at room temperature. Cells were washed twice as described above and dissociation was allowed to proceed in the presence of unlabeled DARPin for the times indicated shaking at room temperature, followed by washes and flow cytometry measurements as described above.
Cell Viability Assays BT474 cells were seeded at a density of 10,000 cells/cm 2 in 96-well-plates (Nunc). After 24 hr, DARPins (or trastuzumab as control) were added and cells were incubated for another 72 hr. Cells were then incubated with 50 ml/well 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT; Roche) for 4 hr at 37 C. Absorbance was measured at 450 nm and expressed as percentage of the untreated controls.
Expression in Insect Cells
Recombinant HER2-ectodomains carrying an N-terminal melittin signal sequence and an N-terminal His 6 tag were expressed in Spodoptera frugiperda (Sf9) cells. Baculoviruses for infection of Sf9 cells were generated using the Multibac system as described (Fitzgerald et al., 2006) . Sf9 cells were grown to a density of 4 3 10 6 cells/mL and coinfected with the respective virus at a MOI of 1. Then 72 hr post infection, cells were harvested by centrifugation (30 min, 5,000 g, 4 C) and the cleared medium was subjected to immobilized metal ion affinity chromatography (IMAC) purification with Ni-NTA Superflow (QIAGEN) purification resin.
X-Ray Crystallography HER2_I and HER2_IV were expressed and purified as described above.
After preincubation with DARPins 9_26_Mut5, 9_29_Mut5 or G3 at equimolar concentrations, complexes were purified via size exclusion chromatography on a Superdex 200 HiLoad 16/60 column equilibrated with TBS150 (PBS, 150 mM NaCl). Eluted protein was concentrated to 14 (9_26/HER2_I), 8 (9_29/HER2_I), or 9 (G3/HER2_IV) mg/ml using Millipore Amicon Ultra 10K centrifugal concentrators. Crystals of the complexes formed in sitting drops mixed with two parts protein solution and one part mother liquor. The mother liquor contained 0.2 M NaCl, 0.1 M phosphate citrate (pH 4.2), and 20% PEG 8000 for 9_26/HER2_I; 0.2 M ammonium acetate (pH 5.6), 0.1 M sodium citrate, 30% (w/v) PEG 4000 for 9_29/HER2_I, or 0.05 M succinic acid and 29% ammonium sulfate (pH 4.0) for G3/HER2_IV, respectively. Crystals grew within 3 days (9_29/HER2_I), 3 weeks (9_26/HER2_I) or 4 weeks (G3/HER2_IV), respectively. They were then transferred to a cryoprotectant solution containing 20% glycerol. Data were collected using the PILATUS 2 M detector system on the PXIII beam line at the Swiss Light Source (Paul Scherrer Institute) and processed using the program XDS (Kabsch, 2010) . The structures were solved by molecular replacement using PHASER MR (McCoy et al., 2007) from within the CCP4 package (CCP4, 1994). Model building was carried out by using the program COOT (Emsley et al., 2010) . The structures were refined using PHENIX (Adams et al., 2010) . Stereochemical properties were analyzed with MOLPROBITY (Davis et al., 2007) and structure figures were generated in PYMOL (http:// pymol.org).
Statistical Analysis
Results from cell viability assays and ELISA experiments were expressed as means from triplicate measurements in bar graphs. Error bars indicate SD.
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